As much as 8% of American children have a food allergy, and some 38% of them suffer from severe allergic reactions.
The prefilled syringe, a rival of Mylan’s widely used EpiPen, is called Symjepi.
He also said the company was still in the process of looking for a distributor and is working on a price when the product goes on the market in the second half of this year. An epinephrine autoinjector serves as a lifeline for these people.
Currently, Mylan Pharmaceuticals’ EpiPen costs in the range of $630 to $700 without insurance.
This photo provided by Adamis Pharmaceuticals Corp. shows the Symjepi syringe, prefilled with the hormone epinephrine, which helps stop life-threatening allergic reactions from insect stings and bites or eating foods such as nuts and eggs.
According to the San Diego-based company, its product was easier to use than Mylan’s EpiPen, a spring-loaded syringe filled with a set dose that came with a training device. Adamis spokesperson Mark Flather, however, said that the company intends to offer the product as a low-priced alternative to Mylan’s autoinjector and that it aims to make it available for less than the price of the generic EpiPens. They haven’t set a specific price yet, but the company’s spokesperson declared they wanted to make it cheaper and more accessible than an EpiPen.
Mylan, which has US headquarters near Pittsburgh, launched generic EpiPens last December in an effort to deflect mounting criticism.
Also on the horizon is a “junior version” of Symjepi, which would contain a lower epinephrine dose and compete with Mylan’s EpiPen Jr.
Mylan has for years owned more than 90 percent of the market for emergency epinephrine injectors and its own authorized generic has recently surpassed sales of the branded version. What makes purchase of EpiPens more burdensome is that these devices have to be replaced each year despite that these may still work four years after their expiry date.